Introduction

71
Breast cancer is the most frequently diagnosed female malignancy in the United States and 72 the second leading cause of cancer-related female deaths [1] . Since the primary tumor is 73 usually resected upon detection, most of this mortality is due to metastases. The 5-year 74 survival for patients diagnosed with localized breast cancer is approximately 99%, indicating 75 that detection and treatment is highly effective when the cancer remains in the breast tissue.
76
However, 5-year survival for patients with overt distant metastases plummets to a dismal 27% 77 [1] . These statistics indicate that the establishment of effective therapies that target and 78 prevent metastasis is of critical importance. Although recent decades have seen significant 79 advances in the development of methods for detection and treatment of primary breast cancer, 80 these treatments are generally ineffective at dampening metastatic progression. Therefore, a 81 better understanding of the mechanisms that regulate and drive metastasis is critical to 82 improving patient outcome.
109 signature [14] [15] [16] . In many cases, these children ultimately die early in life. RNase H2 mutations 110 have also been identified in patients with another autoimmune disease, Systemic Lupus 111 Erythematosus (SLE), though it is not known if these mutations are causative [17] . Given its 112 important role in maintaining genomic integrity, a connection between RNase H2 and cancer is 113 beginning to be investigated, with multiple studies having identified associations between 114 expression of RNase H2 genes and various cancer types [18] [19] [20] [21] [22] [23] [24] [25] .
115 116 We report here the validation of Rnaseh2c as a bona fide metastasis susceptibility gene and 117 reveal its novel function in promoting metastasis through interaction with the immune system, 118 although through an alternate mechanism than that proposed for AGS. This knowledge may 119 contribute to a better understanding of the biology underlying AGS and highlights a potential 120 new target for combination with immune modulatory therapies to combat metastatic breast 121 cancer. This data also adds to a growing panel of genes we have identified that together could 122 help determine patients who are at high risk for developing metastasis.
124
Results 125 Identification of Rnaseh2c as a candidate metastasis susceptibility gene 126 Genetic mapping studies were performed to identify metastasis susceptibility gene candidates.
127
A population of genetically diverse tumor-bearing mice was generated by crossing the FVB/NJ-128 TgN(MMTV-PyMT) 634Mul (hereafter, MMTV-PyMT) mouse model of metastatic breast cancer [26] 129 to animals from the Diversity Outbred mouse mapping panel [27, 28] . 50 DO Generation 5 mice 130 were crossed with MMTV-PyMT, as described in [29] (Fig 1A) . Offspring from the DO x MMTV-134 were calculated for each mouse. The haplotype analysis was integrated with the phenotype 135 data to identify metastasis-associated regions. A total of 17 haplotypes on 11 chromosomes 136 were found to be significantly associated with metastatic disease (FDR < 0.05) (S1 Fig A) .
137
Interestingly, two of the 17 haplotypes overlapped with regions previously identified in genetic 138 studies of metastasis susceptibility: a 1.1 megabase haplotype on chromosome 9 that 139 overlapped the peak of a metastasis susceptibility locus previously found to contain the 140 metastasis susceptibility gene Pvrl1 [7, 11] ; and a 1.3 megabase haplotype on mouse 141 chromosome 19 that overlapped with a previously identified metastasis susceptibility locus 142 which includes the metastasis susceptibility gene Sipa1 [30] . Due to the high density of genes 143 in the chromosome 19 haplotype and the fact that modifier loci can contain multiple causative 144 genes [31] , we selected this region for further screening to identify additional metastasis 145 susceptibility genes that might exist within this interval. Given that polymorphism effects are 146 frequently on gene expression [2] , primary tumor gene expression analysis was performed to 147 identify genes whose expression correlated with pulmonary metastasis. This analysis identified 148 five genes located in the region of interest: Frmd8, Mus81, Rnaseh2c, Pola2, and Dpp3 (S1 Fig   149  B ). Sipa1 was not identified by this screen, consistent with previous studies that demonstrated 150 that the effect of Sipa1 on metastasis was due to a missense polymorphism rather than an 151 expression polymorphism [9] . Interestingly, analysis of patient tumor expression using the 152 GOBO database [32] revealed that the genes within this signature, weighted for expression 153 direction and relative contribution to the signature using the mouse-calculated hazard ratios and 154 grouped by their cumulative signature score, are also able to predict distant metastasis-free 155 survival in breast cancer patients of the Her2-enriched subtype (S1 Fig C) , suggesting that our 156 approach is able to identify haplotypes relevant to outcome in patients as well as in mice.
161
Modulating expression of Rnaseh2c alters spontaneous metastasis 162 To investigate the role of Rnaseh2c as a metastasis modifier gene, shRNA-mediated 163 knockdowns were performed in the mouse metastatic mammary tumor cell line Mvt1.
164
Knockdown was confirmed by qRT-PCR (S2 Fig A) , and the sh2 and sh4 cell lines were 165 selected for future experiments based on western blot analysis ( Fig 1B) . To determine the 166 effects on tumor growth and progression, knockdown Mvt1 cells were orthotopically injected into 167 the mammary fat pad of syngeneic FVB mice. Both knockdown cell lines exhibited significantly 168 reduced numbers of spontaneous pulmonary metastases ( Fig 1C) , indicating that changes in 169
Rnaseh2c expression affect the cell's ability to metastasize. In addition, the sh4 cell line showed 170 reduced primary tumor mass ( Fig 1D) , however both knockdown cell lines maintained the 171 significant reduction in metastasis counts when normalized to their matched primary tumors (Fig   172  1E ). To verify Rnaseh2c's role as a bona fide metastasis modifier, we knocked down Rnaseh2c 173 in a second mouse metastatic mammary cancer cell line, 4T1 (S3 Fig A&B) . In contrast to the 174 primary tumor effect in the Mvt1 cell line, sh2 reduced while sh4 increased primary tumor mass 175 of the 4T1 cells (S3 Fig C) , suggesting that the effect of the shRNAs on tumor mass was 176 independent of Rnaseh2c expression. Again, both knockdown cell lines showed reductions in 177 pulmonary metastases that were maintained upon normalization (S3 Fig D&E) Fig C) and western blot ( Fig 3B) . RER activity analysis revealed that 214 the Rnaseh2a knockdown significantly reduced enzyme RER activity ( Fig 3C) . Spontaneous 215 metastasis assays with the Rnaseh2a knockdown cells produced an increase in primary tumor 216 mass, however there was no significant difference in either the metastasis count or upon 217 normalization (Fig 3 D-F Rnaseh2c knockdown was evaluated both in cell lines (S4 Fig A) and in tumors ( Rnaseh2c knockdown ( Fig 4C) , though expression could be induced by treatment with 246 doxorubicin, a chemotherapeutic that causes DNA damage partially by inducing replication 247 stress through inhibiting topoisomerase II [36] . Given this mechanism of action, we 248 hypothesized that our knockdown cells may be more sensitive to doxorubicin treatment due to 249 cells already experiencing replication stress because of a genomic ribonucleotide burden 250 resulting from disrupted RNase H2 activity. Therefore, we treated control and knockdown cells 251 with increasing concentrations of doxorubicin and measured cell viability. However, the cell lines 252 were equally sensitive to the doxorubicin treatment (S4 Fig D) . In agreement with the p21 data, 253 we also did not observe an induction of γ-H2AX signal in our knockdown cells (S5 Fig) Fig A) . Unexpectedly, in knockdown cells, staining 262 was slightly reduced in the sh2 and drastically reduced in the sh4 cells including in the nuclei 263 (S6 Fig A) , suggesting that hybrids were not accumulating despite reduced RNase H2 enzyme 264 activity. We hypothesized that this could be due to a compensatory upregulation of Rnaseh1, 265 which also removes longer RNA moieties from RNA/DNA hybrids. We found that RNASEH1 266 expression was indeed increased upon Rnaseh2c knockdown (S6 Fig B) . To test whether 267
Rnaseh2c knockdown alters enzyme activity against RNA/DNA hybrids, we repeated the 268 enzyme activity assay using an oligo substrate composed of an RNA strand hybridized to a 269 DNA strand. This analysis revealed no difference between the control and Rnaseh2c 270 knockdown cells (S6 Fig C) , suggesting that RNase H1 upregulation helps maintain activity 271 against RNA/DNA hybrids.
273
Together, these data show that despite a significant reduction in RNase H2 enzyme activity, the 274 expected effects of enzyme dysfunction are not observed in our cancer cells, suggesting there 275 may be other enzyme-independent effects taking place. We therefore expanded our 276 investigation into other potential effects of reduced enzyme activity. Interferon Gamma Response and Interferon Alpha Response gene sets ( Fig 5A) . For more 288 specific pathway annotations, genes with expression changes of at least two-fold in either 289 direction (249 genes, 169 of which exhibited a positive fold change) were assigned to biological 290 pathways and analyzed by Ingenuity Pathway Analysis (S1 File). Of the top 25 significantly 291 altered pathways, 17 were related to T cell responses (Table 1) . Furthermore, more than half (8 292 of 17) of these pathways produced positive Z-scores, indicating that the direction of transcript 293 change is consistent with the pathway being activated in knockdown tumors. orthotopic metastasis assays were performed using athymic nude mice, which lack mature T 313 cells. While the previously observed significant reduction in sh4 primary tumor mass was 314 maintained (Fig 5B) , the pulmonary metastasis effect was ablated ( Fig 5C) indicating that the 315 Rnaseh2c metastasis effect functions through engagement of T cell-mediated immunity.
317
To further delineate which T cell populations were involved, immunophenotyping was performed 318 using tissue from the primary tumors, metastatic lungs, and spleens of mice orthotopically 319 injected with the scramble control or knockdown cell lines. FACS analysis revealed the activated 320 CD8+ T cell population (CD8+ IFN-γ+) was significantly increased in both the primary tumor and 321 metastatic lung samples of knockdown mice compared to controls (Fig 5 D&E) . This increase 322 was not observed in the spleen (S8 Fig C) , demonstrating that the effect was specific to the 323 primary tumor and metastatic sites. CD4+ Foxp3+ T regulatory cells were also affected by 324
Rnaseh2c knockdown, but their reduction was restricted to the metastatic lung at the time of 325 tissue harvest; NK cell infiltration was not affected (S8 Fig A&B) . Together these data show that 326 the immune system plays an important role in Rnaseh2c-mediated changes in metastasis.
327 328 IRF3 activation, the proposed mechanism of AGS, is not observed upon 329
Rnaseh2c knockdown in Mvt1 cells
330 Given that AGS also has an inflammatory component, we tested whether the current 331 mechanism of this disease could also apply to our metastasis model. Recent AGS research has 332 suggested that the cytosolic DNA-sensing cGAS-STING pathway is activated via IFR3 signaling 333 in patients and mouse models of AGS [39] [40] [41] . This pathway leads to activation of Type I 334 interferons and the production of interferon-stimulated genes to generate an immune response.
335
We measured the production of a panel of interferon-related genes -including a subset known 336 to be increased in AGS patients -in our Rnaseh2c knockdown cells using qRT-PCR. Of the 10 337 genes that were tested, 3 interferon-related genes showed a trending (p < 0.10) or significant (p 338 < 0.05) increase in one or both knockdown cell lines ( Fig 6A) . These data indicate that Rnaseh2c knockdown results in a subtle upregulation of certain interferon-stimulated genes in 340 vitro. To determine whether IRF3 is inducing these expression changes, IRF3 activation was 341 examined. Although IRF3 could be phosphorylated and translocate to the nucleus in response 342 to treatment with the STING activator DMXAA, these effects were not observed in response to 343 Rnaseh2c knockdown alone ( Fig 6B) . NF-κB activation, which can also be induced by cGAS-344 STING signaling, was also examined. However, neither the canonical nor non-canonical NF-κB 345 signaling pathways were shown to be activated (S9 Fig A&B) . Fig D) , thus further analysis was not pursued. For noncoding 362 RNAs, total RNA-sequencing of scramble control and sh4 knockdown cell lines was performed.
363
Comparison of significantly differentially expressed noncoding RNAs produced a list of only 20 transcripts of three types: 14 antisense RNAs, 4 long intergenic noncoding RNAs, and 2 365 processed transcripts (S1 Table) . Notably, this analysis also did not identify any differences in 
377
These samples were selected to enrich for cells capable of completing the metastatic cascade 378 that might otherwise be cleared by the adaptive immune response in immunocompetent mice.
379
Comparing exonic variant counts between control and knockdown metastases showed that 380 there was not an increase in mutation burden with dysfunctional RNase H2 (S9 Fig E) , was observed upon Rnaseh2c knockdown. These observations suggest that the mechanism 426 governing the immune activation in AGS may be different from the mechanism at play in breast 427 cancer and metastasis, despite immune activation being common to the two diseases. In 428 addition, the experiments that identified the involvement of cGAS-STING in AGS were done 429 using mutations [39] or with knockout of a subunit [40] that were known to affect enzyme 430 activity, thus it is not known whether this mechanism applies in a scenario of reduced 431 expression or to enzyme-independent effects. It is also possible that the Interferon-stimulated 432 gene activation is resulting from signaling of a non-canonical anti-viral response that was not 433 tested here. Alternatively, these data may suggest that our in vitro condition does not fully The results from our study reveal an important role for the immune system in limiting Rnaseh2c-470 mediated metastatic disease through the cytotoxic T cell response. The involvement of the 471 immune system may also help explain the results of the experimental (tail vein) metastasis 472 assay. Unlike in spontaneous metastasis assays where the immune system is exposed to the 473 developing tumor and thus primed to attack metastasizing cells, the immune system of the 474 mouse receiving cells by tail vein injection has not been exposed to these cells prior to their 475 bolus introduction into circulation and arrival in the lung. Therefore, the tumor-induced priming of 476 the pulmonary immune microenvironment seen by spontaneously metastasizing cells would be 477 absent in the experimental metastasis setting. In addition, the immune response at the primary 478 tumor may be preventing cells from escaping, thus also ultimately preventing lung colonization.
479
Both interpretations fit the observed results of the metastasis assays; additional study will be 480 needed to determine whether either is accurate. Immunofluorescence 607 Cells were grown to approximately 50% confluency on 12 mm diameter cover slips and 608 incubated overnight. Cells were washed twice in PBS and fixed with 4% formaldehyde or ice-609 cold methanol for 15 min, followed by two washes. Cells were treated with 10 mM glycine for 20 610 min and washed twice. Cells were then permeabilized with 0.1% Triton-X for 20 min, washed at 611 least 3 times, and blocked with 5% goat serum for 1 hr followed by a wash in 0.1% BSA in PBS.
612
Antibodies were prepared by dilution in 0.1% BSA in PBS and spun at 4 ℃ for 10 min at 613 maximum speed. For staining, cells were incubated with primary antibody for 1 hr at room 614 temperature to overnight at 4 ℃ followed by a wash in dilution buffer, followed by incubation in 615 secondary antibody for 1 hr at room temperature. Cells were washed in dilution buffer, counter 616 stained with DAPI, and mounted on slides for visualization. Antibodies used were as follows: 
Figure Legends
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(A) RNASEH2C protein expression by western blot following exogenous overexpression (OE).
992
One representative blot is shown, average relative densitometry for three independent 993 experiments is reported below; OE lane is combined endogenous and exogenous tagged Fig 5. T cells mediate the effect of Rnaseh2c knockdown on metastasis.
